Pulmonx Corp LUNG
We take great care to ensure that the data presented and summarized in this overview for Pulmonx Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LUNG
View all-
Primecap Management CO Pasadena, CA5.51MShares$24.9 Million0.03% of portfolio
-
Morgan Stanley New York, NY3.07MShares$13.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$12.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$10.3 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.53MShares$6.94 Million0.26% of portfolio
-
Bnp Paribas Asset Management Holding S.A.1.25MShares$5.66 Million0.02% of portfolio
-
Jefferies Group LLC New York, NY1.2MShares$5.43 Million0.2% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.1MShares$4.98 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA902KShares$4.08 Million0.0% of portfolio
-
Altium Capital Management LP New York, NY815KShares$3.68 Million1.84% of portfolio
Latest Institutional Activity in LUNG
Top Purchases
Top Sells
About LUNG
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Insider Transactions at LUNG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 20
2025
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
20,000
-1.98%
|
$140,000
$7.85 P/Share
|
|
Mar 03
2025
|
Mehul Joshi Chief Financial Officer & PAO |
BUY
Grant, award, or other acquisition
|
Direct |
108,000
+32.73%
|
-
|
|
Mar 03
2025
|
Mehul Joshi Chief Financial Officer & PAO |
SELL
Open market or private sale
|
Direct |
14,384
-11.21%
|
$100,688
$7.12 P/Share
|
|
Mar 03
2025
|
David Aaron Lehman GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
108,000
+27.59%
|
-
|
|
Mar 03
2025
|
David Aaron Lehman GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
22,355
-2.34%
|
$156,485
$7.31 P/Share
|
|
Mar 03
2025
|
Steven S. Williamson PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
181,696
+32.58%
|
-
|
|
Mar 03
2025
|
Steven S. Williamson PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
27,689
-12.47%
|
$193,823
$7.14 P/Share
|
|
Mar 03
2025
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
108,000
+21.54%
|
-
|
|
Mar 03
2025
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,779
-0.5%
|
$40,453
$7.13 P/Share
|
|
Feb 20
2025
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
55,453
-2.62%
|
$443,624
$8.45 P/Share
|
|
Jan 17
2025
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
2,221
-0.21%
|
$13,326
$6.5 P/Share
|
|
Jan 16
2025
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
2,326
-0.22%
|
$13,956
$6.53 P/Share
|
|
Dec 02
2024
|
David Aaron Lehman GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
5,497
-0.68%
|
$32,982
$6.19 P/Share
|
|
Dec 02
2024
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,376
-0.37%
|
$26,256
$6.19 P/Share
|
|
Nov 22
2024
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
20,000
-1.83%
|
$120,000
$6.63 P/Share
|
|
Oct 17
2024
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
20,000
-1.8%
|
$120,000
$6.52 P/Share
|
|
Sep 12
2024
|
Glendon E. French Iii |
SELL
Open market or private sale
|
Direct |
20,000
-1.77%
|
$160,000
$8.09 P/Share
|
|
Sep 03
2024
|
Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,586
-0.38%
|
$27,516
$6.7 P/Share
|
|
Sep 03
2024
|
David Aaron Lehman GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
5,765
-0.7%
|
$34,590
$6.7 P/Share
|
|
Aug 20
2024
|
Steven S. Williamson PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
14,245
+6.09%
|
$85,470
$6.84 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 738K shares |
|---|---|
| Open market or private purchase | 14.2K shares |
| Open market or private sale | 243K shares |
|---|